





PIPELINE

Candidate: Lasofoxifene – Oral SERM

Monotherapy ●
 Combination Therapy ●●

► Breast Cancer

	Preclinical	Phase 1	Phase 2	Phase 3/4
●	ELAINE 1: Lasofoxifene vs. Fulvestrant 			<input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>
●●	ELAINE 2: Laso + Abemaciclib 			<input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>
●	ELAINE 3: Lasofoxifene vs. Fulvestrant 			<input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>
●●	ELAINE 4: Laso + CDK 4/6 Inhibitor 			<input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>
●●	Laso + mTOR Inhibitor			<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
●●	Laso + AKT Inhibitor			<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

In Planning
 Enrollment Complete
 Potentially Registrational

Lilly

tbcrc

▶ Treatment Resistant Tumors (non-ESR1^{mut}) and ESR1^{mut}

-
-

Laso vs. Fulv

Laso + Palbo
vs. Fulv + Palbo

▶ Gynecological Cancer

- /••

Lasofloxifene –
Endometrial
Cancer

▶ ESR1 Assay

Research Assay

Clinical Trial
Assay (CTA)

CTA/CDx

THE UNIVERSITY OF
CHICAGO

UNIVERSITY OF UTAH
HUNTSMAN
CANCER INSTITUTE